Compare CTS & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTS | PGEN |
|---|---|---|
| Founded | 1896 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | 1994 | 2013 |
| Metric | CTS | PGEN |
|---|---|---|
| Price | $60.23 | $5.34 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $8.33 |
| AVG Volume (30 Days) | 350.7K | ★ 5.1M |
| Earning Date | 04-29-2026 | 05-13-2026 |
| Dividend Yield | ★ 0.29% | N/A |
| EPS Growth | ★ 15.87 | N/A |
| EPS | ★ 0.59 | N/A |
| Revenue | ★ $541,318,000.00 | $230,981,000.00 |
| Revenue This Year | $5.55 | $1,115.92 |
| Revenue Next Year | $5.00 | $81.04 |
| P/E Ratio | $103.93 | ★ N/A |
| Revenue Growth | ★ 4.95 | N/A |
| 52 Week Low | $36.03 | $1.54 |
| 52 Week High | $69.55 | $6.04 |
| Indicator | CTS | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 45.89 | 55.58 |
| Support Level | $54.75 | $5.20 |
| Resistance Level | $62.02 | $5.47 |
| Average True Range (ATR) | 1.98 | 0.29 |
| MACD | -0.06 | -0.06 |
| Stochastic Oscillator | 45.12 | 54.31 |
CTS Corp operates in the electronics industry. The company is a manufacturer of Sensors, Electronic components, and Actuators. It designs, manufactures, and sells a broad line of sensors, electronic components, and actuators mainly to original equipment manufacturers (OEMs) for the aerospace and defense, industrial, information technology, medical, telecommunications, and transportation markets. Geographically, it derives a majority of its revenue from the United States and also has a presence in China, Singapore, the Czech Republic, Taiwan, Denmark, and other countries.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.